Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
International Journal of Molecular Medicine
Join Editorial Board Propose a Special Issue
Print ISSN: 1107-3756 Online ISSN: 1791-244X
Journal Cover
November 2012 Volume 30 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
November 2012 Volume 30 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

microRNA expression profiling of the developing mouse heart

  • Authors:
    • Li Cao
    • Li-Ping Kong
    • Zhang-Bin Yu
    • Shu-Ping Han
    • Yun-Fei Bai
    • Jingai Zhu
    • Xiaoshan Hu
    • Chun Zhu
    • Shasha Zhu
    • Xi-Rong Guo
  • View Affiliations / Copyright

    Affiliations: State Key Laboratory of Reproductive Medicine, Department of Ultrasound, Nanjing Maternal and Child Health Hospital, Nanjing Medical University, Nanjing 210029, P.R. China, State Key Laboratory of Reproductive Medicine, Department of Pediatrics, Nanjing Maternity and Child Health Care Hospital Affiliated to Nanjing Medical University, Nanjing 210029, P.R. China, State Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, P.R. China
  • Pages: 1095-1104
    |
    Published online on: August 9, 2012
       https://doi.org/10.3892/ijmm.2012.1092
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

microRNAs (miRNAs) play an important role in regulating normal organ physiology and development. Many miRNAs show spatially and temporally restricted expression patterns during embryogenesis and organogenesis. This study aimed to characterize the miRNA profile of the fetal mouse heart at 4 key time-points [embryonic day (E)12.5, E14.5, E16.5 and E18.5] in its development, by performing a sequencing by oligonucleotide ligation and detection (SOLiD) miRNA screen. The 4 time-points were designated as groups M1 (E18.5), M2 (E16.5), M3 (E14.5) and M4 (E12.5). miRNAs found to have consistent fold-changes of >2.0) between the 4 time-points were selected for further analysis. Ten miRNAs (mmu-miR-23b, mmu-miR-24, mmu-miR-23a, mmu-miR-375, mmu-miR-29a, mmu-miR-93, mmu-miR-21, mmu-miR-25, mmu-let-7b and mmu-miR-27b) that were the most highly expressed in the 4 groups, including the percentage >1% of total read counts, were identified. No miRNA was consistently downregulated or upregulated. There were 16 differentially expressed miRNAs between the later development group (M1+M2) and the early development group (M3+M4), which were validated by quantitative real-time PCR. Several members of the let-7 miRNA cluster (mmu-let-7a/7d/7e/7f) were upregulated in the later development group compared with the early development group. A network analysis of the predicted targets of mmu-let-7a/7d/7e/7f identified 5 target genes (FOXP1, TBX5, HAND1, AKT2 and PPARGC1A), known to be involved in cardiac development. Therefore, this study identified several miRNAs that are abundantly expressed in the developing heart, several of which are differentially expressed in the 4 time-points studied. Findings of this analysis may thus clarify the mechanisms of normal heart development and provide a physiological basis for future studies on congenital heart disease.

Introduction

microRNAs (miRNAs) are a class of RNA molecules, typically 19–25 nucleotides (nt) long, comprising highly conserved families of non-coding RNA that have gained recognition as important regulators of diverse cell processes, such as proliferation, differentiation, development, and cell death (1). miRNAs are negative regulators of gene expression that inhibit the translation or promote the degradation of target mRNAs, with an estimated 30% of transcribed mRNAs thought to be susceptible to miRNA-mediated regulation (2).

miRNAs play an important role in regulating normal organ physiology and development (3). The elucidation of the spatial and temporal patterns of their expression is important for understanding the precise role of miRNAs in organogenesis (4). To gain a more complete understanding of miRNA functions, investigations were conducted into global patterns of miRNA expression in mammalian tissues, and a number of miRNAs enriched in specific tissues were identified (5). Although the spatial and temporal expression patterns of some developing mouse tissues, such as, retina, bladder and brain, have been analyzed, those of the heart remain to be investiagated (6–8). Through this process, specific miRNAs at critical stages of organ development have been identified and quantified, providing valuable insight into their role during organogenesis.

Findings of previous studies suggested that miRNAs play an essential role in the maintenance of cardiac development and disease (9). A series of studies, profiling miRNA expression in rodent and human hearts under various pathological conditions, including cardiac hypertrophy, heart failure and myocardial infarction demonstrated that miRNAs are involved in cardiac pathophysiology (10–12). The global patterns of miRNA expression of normal human and mouse heart have been profiled in adults (3). Furthermore, some cardiac-specific miRNAs, including miR-1, miR-133a and miR-208a, involved in maintaining cardiac development and function have been identified (13–15).

However, the heart, more than any other organ, has to maintain a high level of function throughout the lifespan of the organism, starting from the early primitive heart tube, to formation of the heart chambers, and throughout life (16). It is known that many miRNAs show spatially and/or temporally restricted expression patterns (17). Thus, by characterizing the spatial and temporal expression profiles of miRNAs in the developing heart, we can improve our understanding of heart development and gene regulation. The differentially expressed miRNAs of mouse ventricular chambers in 3 distinct developmental stages [embryonic day (E)12.5, E15.5 and E18.5] have been profiled (18). Most of the differentially expressed miRNAs exhibited a relatively discrete peak of expression at ventricular developmental stages; however, spatial and temporal expression profiles of miRNAs in heart have not been examined in detail.

The mouse heart shows great similarity to the human heart, with respect to anatomy, growth and development, making the mouse an important experimental model for biomedical research (19). The heart is the first functional organ during mouse embryonic development. During this stage, the primitive heart tube, in which the heart begins to beat at approximately the E9.0, begins to form. The form of the heart starts to take shape at approximately E10.0, and at E12.5–18.5, the tube undergoes a complex series of movements and tissue remodeling events that lead to the formation of the 4-chambered heart (20). Based on this developmental timeline, we selected 4 key time-points (E12.5, E14.5, E16.5 and E18.5) representing the process of normal heart development, to perform a miRNA screening by next-generation sequencing in C57BL/6 mice. The aim of this study was to explore the mechanisms of miRNAs in embryonic heart development, and offer a foundation for future functional analyses.

Materials and methods

Experimental animals

The Nanjing Medical University Animal Care and Use Committee approved the experimental protocols used in this study. Pathogen-free male and female C57BL/6J mice were obtained from the animal center of the Nanjing Medical University. The animals were housed in individual cases in a temperature-controlled room with a 12-h light/dark cycle. At the age of 6 months, the males and females were mated. Pregnancy was detected by visual inspection of a distended abdomen. At E12.5, E14.5, E16.5 and E18.5, pregnant mice were sacrificed with CO2, embryos were collected and fetal hearts dissected and pooled within each age group for further analysis. The 4 experimental groups were designated as: M1 (E18.5), M2 (E16.5), M3 (E14.5) and M4 (E12.5).

Hematoxylin and eosin (H&E) staining

Collected fetal hearts were washed with cold PBS and then fixed in formalin overnight at 4°C. Sections (7 μm) of paraformaldehyde-fixed heart tissue were obtained and stained with H&E for morphological analysis. H&E sections were viewed under a light microscope at magnifications of ×40 to observe changes in fetal heart development at the 4 experimental time-points.

Isolation of miRNA, and sequencing by oligonucleotide ligation and detection (SOLiD) sequencing and analysis

At each time point, fetal cardiac tissue was removed, snap-frozen in liquid nitrogen and stored at −80°C for later analysis. Total miRNA was extracted from cardiac tissue of fetal mice using the mirVana miRNA Isolation kit (Applied Biosystems-Life Technologies Co., Grand Island, NY, USA) according to the manufacturer’s instructions.

The methodological details of sample processing, RNA extraction, library construction, and SOLiD sequencing were described in our previous study (21). Samples of miRNA (100 ng) isolated from cardiac tissue of fetal mouse were processed into sequencing libraries using the Small RNA Expression kit (Applied Biosystems). Briefly, RNA was ligated overnight with the adapters from the kit, reverse-transcribed, RNAse H-treated and PCR amplified before agarose gel electrophoresis for size selection of miRNAs containing inserted sequences of 16–61 nt. Libraries were amplified onto beads using emulsion PCR, deposited on slides and sequenced using the SOLiD v2 sequencing system (Applied Biosystems) at the State Key Laboratory of Bioelectronics, Southeast University, China. Data were analyzed with the SOLiD System Small RNA Analysis Pipeline Tool (RNA2MAP). Acceptable sequences were compared with sequences in the mouse miRBase database (release 14.0, http://www.mirbase.org; Sanger). The threshold for selection was set conservatively to include beads sampled a minimum of 10 times in any of the libraries.

Quantitative real-time PCR

The methodological details of quantitative real-time PCR (qRT-PCR) were described in our previous study (21), which was performed to confirm the differential expression of miRNAs identified by SOLiD sequencing. Briefly, total RNA was isolated from cardiac tissue of fetal mice using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Single-strand cDNA was synthesized as follows: the reverse transcription mixture contained 2 μl total RNA, 1 μl mmu-miRNA reverse primer (Table I), 1 μl ReverTra Ace, 4 μl 5X buffer, 2 μl dNTP mix (10 mM), 1 μl RNasin, 1 μl random primer and 8 μl RNase-Free H2O (20 μl total volume). The reaction was performed according to the manufacturer’s instructions using the Applied Biosystems 7300 real-time PCR system (Applied Biosystems) (Table II). Data were analyzed using an iCycler™ iQ Optical System Software, Version 3.0a (Bio-Rad Laboratories, Hercules, CA, USA). The relative level of mmu-miRNA was calculated relative to U6 RNA (internal control) using the 2−ΔΔCt method.

Table I.

RT primer sequences.

Table I.

RT primer sequences.

Gene nameRT primers
let-7a 5′-CGTCGCGGCATCGAGTGGAGCAGACCGACAGCGCGACGGATTAGGAAAGA-3′
let-7d 5′-CGTCGCGGCATCGAGTGGAGCAGACCGACAGCGCGACGGATAAGAAAGGC-3′
let-7e 5′-CGTCGCGGCATCGAGTGGAGCAGACCGACAGCGCGATATACAACCTCC-3′
let-7f 5′-CGTCGCGGCATCGAGTGGAGCAGACCGACAGCGCGACGGATATACAATCTA-3′
miR-206 5′-CGTCGCGGCATCGAGTGGAGCAGACCGACAGCGCGACGGCCACATGC-3′
miR-184 5′-CGTCGCGGCATCGAGTGGAGCAGACCGACAGCGCGACGACCTACCCTT-3′
miR-146b 5′-CGTCGCGGCATCGAGTGGAGCAGACCGACAGCGCGACGGAGAACTTTG-3′

Table II.

Primers for real-time RT-PCR.

Table II.

Primers for real-time RT-PCR.

Gene nameForward primerReverse primer
let-7a 5′-GCTACTGTCTTTCCTAAG-3′ 5′-GCATCGAGTGGAGCAGAC-3′
let-7d 5′-TTAACTATACGACCTGCTGC-3′ 5′-GCATCGAGTGGAGCAGAC-3′
let-7e 5′-GGGTGAGGTAGGAGGTTGTATA-3′ 5′-GCATCGAGTGGAGCAGAC-3′
let-7f 5′-GGTGAGGTAGTAGATTGTATA-3′ 5′-GCATCGAGTGGAGCAGAC-3′
miR-206 5′-GGATATAAAGAAGCATGT-3′ 5′-GCATCGAGTGGAGCAGACC-3′
miR-184 5′-GAACTGATAAGGGTAGGA-3′ 5′-GCATCGAGTGGAGCAGAC-3′
miR-146b 5′-GGTGGCCAAAGTTCTCTCA-3′ 5′-GCATCGAGTGGAGCAGAC-3′
U6 5′-CAGGGGCCATGCTAAATCTTC-3′ 5′-CTTCGGCAGCACATATACTAAAAT-3′
Target gene ontology and network analysis of target gene-miRNAs

The methodological details of target gene ontology and network analysis of target gene-miRNAs were described in our previous study (21). In brief, target genes were analyzed by gene ontology (http://www.babelomics.bioinfo.cipf.es/). A graphical representation of the network between the miRNAs and their predicted targets involved in cardiac development was identified by IPA analysis (http://www.ingenuity.com/).

Statistical analysis

Putative miRNA candidates were selected according to the following criteria: i) at least 10 copies by SOLiD sequencing; ii) fold-change >2, based on the normalized counts between different time-points (M1 vs. M2, M1 vs. M3, M1 vs. M4, M2 vs. M3, M2 vs. M4 and M3 vs. M4), as well as between the later development group (M1+M2) and early development group (M3+M4); iii) the data of the qRT-PCR were presented as the mean ± SEM. P<0.05 was considered statistically significant.

Results

Overview of the SOLiD sequencing data

After SOLiD sequencing, raw reads were obtained from the small RNA library. Low-quality reads were removed, and the 39 adaptor sequences were trimmed. Small RNA sequences ranging in size from 18 to 28 nt were retrieved from the raw data set. The size distributions of the reads are shown in Fig. 1. The majority of the small RNAs were between 21 and 23 nt in size. Sequences of 22 nt accounted for 31.5–37.3% of total sequence reads in the 4 samples, which is the typical size range for Dicer-derived products. The 23 nt size class was also dominant.

Figure 1.

Distribution of sequenced miRNAs by their number of nucleotides.

Histology

A series of hearts were collected at each time point for histological analysis using H&E (Fig. 2). The typical features of the developing heart were observed at each time point: in the M4 group, the endocardial cushions appeared to fuse, and the sepals, aorta and tracheal were also visible. In the M3 group, aortic and pulmonary arterial structures were found to be well-developed, and the left ventricular outflow tract, the inflow tract and mitral valve were all visible. In the M2 group, the myocardium had completed development. In the M1 group, the endocardial, myocardial and epicardial layers had matured.

Figure 2.

Morphological stages of heart development at the 4 time-points used for miRNA profiling. Images of the whole heart (A, C, E and G) and corresponding tissue sections stained with H&E (B, D, F and H) are shown for each time point studied (E12.5, E14.5, E16.5 and E18.5, from top to bottom).

miRNA expression profile

The expression profiles of miRNAs in the cardiac tissue of fetal mice were analyzed in 4 samples. The top expressed miRNAs of the 4 groups are shown in Table III, including miRNAs present at >1% of total read counts. The types of the top expressed miRNAs gradually increased along with the increasing gestational age from E12.5 to E18.5. The 10 miRNAs included in the top expressed miRNAs of the 4 groups are: mmu-miR-23b, mmu-miR-24, mmu-miR-23a, mmu-miR-375, mmu-miR-29a, mmu-miR-93, mmu-miR-21, mmu-miR-25, mmu-let-7b and mmu-miR-27b.

Table III.

The top expressed miRNAs in the developing heart.

Table III.

The top expressed miRNAs in the developing heart.

M1 (E18.5)
M2 (E16.5)
M3 (E14.5)
M4 (E12.5)
miRNA%miRNA%miRNA%miRNA%
mmu-miR-23b22.07mmu-miR-23b22.89mmu-miR-23b32.09mmu-miR-23b30.65
mmu-miR-23a13.99mmu-miR-2417.07mmu-miR-2418.42mmu-miR-2418.11
mmu-miR-2410.94mmu-miR-23a8.79mmu-miR-23a11.41mmu-miR-23a10.77
mmu-miR-2215.47mmu-miR-3757.36mmu-miR-3755.30mmu-miR-3757.54
mmu-miR-3754.37mmu-miR-933.08mmu-miR-29a2.96mmu-miR-29a2.41
mmu-miR-29a4.25mmu-miR-29a2.91mmu-miR-932.68mmu-miR-932.28
mmu-miR-932.30mmu-let-7a2.17mmu-miR-211.26mmu-miR-211.58
mmu-miR-212.16mmu-miR-3511.60mmu-miR-27b1.22mmu-miR-251.58
mmu-miR-2222.03mmu-miR-251.54mmu-miR-251.22mmu-let-7b1.52
mmu-let-7b1.80mmu-let-7f1.48mmu-let-7b1.16mmu-miR-27b1.39
mmu-let-7a1.76mmu-let-7b1.43mmu-miR-3201.02
mmu-miR-27b1.23mmu-miR-26a1.37
mmu-miR-251.23mmu-miR-181d1.37
mmu-miR-26a1.21mmu-miR-27b1.31
mmu-let-7f1.20mmu-miR-181b1.20
mmu-miR-221.06

We used a threshold of at least 10 copies by SOLiD sequencing in the 4 groups, and found 80 miRNAs that met those requirements. These miRNAs were used for further hierarchical cluster analysis (Fig. 3). As a result, 77 differentially expressed miRNAs in the 4 groups (M1, M2, M3 and M4) passed our fold-change filter (fold-change >2.0), including 51 differentially upregulated miRNAs and 26 differentially downregulated miRNAs (Tables IV and V). Among the differentially expressed miRNAs, we identified 8 downregulated and 6 upregulated miRNAs in M1/M2; 2 downregulated and 8 upregulated miRNAs in M1/M3; 5 downregulated and 7 upregulated miRNAs in M1/M4; 3 downregulated and 13 upregulated miRNAs in M2/M3; 3 downregulated and 13 upregulated miRNAs in M2/M4; 5 downregulated and 4 upregulated miRNAs in M3/M4, all with a fold-change >2 (Tables IV and V). From this list of differentially expressed miRNAs, we aimed to identify miRNAs that were consistently downregulated or upregulated during heart development, however, no miRNA met these requirements.

Figure 3.

Hierarchical miRNA clustering of groups M1, M2, M3 and M4. Distinguishable miRNA expression profiling is observed. Red indicates high relative expression, whereas green indicates low relative expression and black represents 0.

Table IV.

Differentially expressed miRNAs upregulated in the developing heart.

Table IV.

Differentially expressed miRNAs upregulated in the developing heart.

M1 vs. M2
M1 vs. M3
M1 vs. M4
M2 vs. M3
M2 vs. M4
M3 vs. M4
miRNARatiomiRNARatiomiRNARatiomiRNARatiomiRNARatiomiRNARatio
mmu-miR-22147.88mmu-miR-22253.42mmu-miR-22128.77mmu-miR-22210.52mmu-let-7f7.81mmu-miR-1843.51
mmu-miR-2225.08mmu-miR-22143.50mmu-let-7f6.31mmu-miR-3516.77mmu-miR-3516.31mmu-let-7c2.94
mmu-miR-181b4.84mmu-miR-2149.83mmu-miR-2225.34mmu-miR-2146.39mmu-miR-181d4.33mmu-miR-151-3p2.42
mmu-miR-212.70mmu-let-7f3.20mmu-let-7c4.65mmu-miR-15b6.24mmu-let-7a3.81mmu-miR-1852.18
mmu-miR-21332.51mmu-let-7d2.51mmu-miR-223.35mmu-miR-181b5.71mmu-miR-15b3.61
mmu-miR-222.06mmu-miR-181b2.34mmu-let-7a3.09mmu-let-7d5.07mmu-let-7c3.61
mmu-miR-222.20mmu-miR-1852.25mmu-miR-181d5.05mmu-miR-181b3.15
mmu-miR-125a-5p2.05mmu-miR-181c4.06mmu-let-7d3.15
mmu-let-7f3.96mmu-miR-181a3.15
mmu-miR-30c2.68mmu-miR-7b2.70
mmu-let-7a2.29mmu-miR-148b2.70
mmu-miR-2982.23mmu-miR-151-3p2.70
mmu-miR-125a-5p2.20mmu-miR-1852.52
mmu-miR-7b2.01 mmu-miR-125a-5p2.40

Table V.

Differentially expressed miRNAs downregulated in the developing heart.

Table V.

Differentially expressed miRNAs downregulated in the developing heart.

M1 vs. M2
M1 vs. M3
M1 vs. M4
M2 vs. M3
M2 vs. M4
M3 vs. M4
miRNARatiomiRNARatiomiRNARatiomiRNARatiomiRNARatiomiRNARatio
mmu-miR-3610.45mmu-miR-1850.44mmu-miR-3610.49mmu-miR-21330.41mmu-miR-671-5p0.30mmu-miR-1030.49
mmu-miR-148b0.42mmu-miR-26b0.35mmu-miR-26b0.49mmu-miR-1840.17mmu-miR-1030.25mmu-miR-181c0.44
mmu-miR-181b0.41mmu-miR-2980.42mmu-miR-1830.16mmu-miR-1830.20mmu-miR-26b0.44
mmu-miR-1850.38mmu-miR-671-5p0.41mmu-miR-2140.14
mmu-miR-181c0.32mmu-miR-1030.41mmu-miR-2220.10
mmu-miR-1380.30
mmu-miR-15b0.15
mmu-miR-26b0.14

Since there was no miRNA showing obvious fold-changes consistently between the 4 groups, we re-analyzed our data to profile the differentially expressed miRNAs between the later development group (M1+M2) and the early development group (M3+M4). Using this analysis 16 differentially expressed miRNAs located in 11 chromosomes were identified (Table VI), 3 of which were downregulated and 13 of which were upregulated, with a fold-change >2.

Table VI.

Differentially expressed miRNAs of the fetal mouse heart the between late development and early development groups.

Table VI.

Differentially expressed miRNAs of the fetal mouse heart the between late development and early development groups.

miRNA(M1+M2) vs. (M3+M4)Log2 [(M1+M2)/(M3+M4)]Chromosomal localizationStart locusStop locus
mmu-miR-1278.903.1512110040653110040722
mmu-miR-315.182.3748838178888381893
mmu-let-7f4.752.25134863319848633286
mmu-let-7e3.781.92171753497017535062
mmu-miR-532-5p3.091.63X64053616405456
mmu-miR-92a3.031.6014115443649115443728
mmu-let-7d2.911.54134863138148631483
mmu-miR-15b2.631.4036881369468813757
mmu-let-7a2.591.37134863354848633641
mmu-miR-148a2.411.2765121981151219909
mmu-miR-181a2.361.241139863032139863118
mmu-miR-532-3p2.231.16X68255286825623
mmu-miR-125a-5p2.221.15171796777617967843
mmu-miR-2060.46−1.1212066909120669163
mmu-miR-1840.41−1.2998969709889697166
mmu-miR-146b0.34−1.56194641725246417360
Validation of differentially expressed miRNAs

SOLiD sequencing results were validated by qRT-PCR expression analysis in the later development and early development groups. Upregulated miRNAs (mmu-let-7a, mmu-let-7d, mmu-let-7e and mmu-let-7f) and downregulated miRNAs (mmu-miR-206, mmu-miR-184 and mmu-miR-146b) were selected for additional analysis. This confirmatory process showed that our expression data obtained by qRT-PCR analysis were comparable with the sequencing data (Fig. 4).

Figure 4.

Quantification of miRNA expression levels of fetal mouse cardiac tissue in the early development and later development groups by qRT-PCR. Values on the Y-axis are the ratio of 2 groups of miRNAs calculated using the equation Log2 [(M1+M2)/(M3+M4)].

Target gene ontology and target gene-miRNA network analysis

Of the miRNAs identified for additional analysis, a subset (mmu-let-7a, mmu-let-7d, mmu-let-7e and mmu-let-7f) was found to be from the same polycistronic miRNA cluster (let-7), and were upregulated when comparing the later development group with the early development group. Predicted targets of the 4 differentially expressed miRNAs of the let-7 cluster were grouped into different categories. The top 13 gene ontology (GO) terms are shown in Table VII. The majority of targets were classified according to developmental processes, cell organization and biogenesis, thus reflecting the profound biological changes occurring in the developing mouse heart. A network relationship between the predicted targets of the 4 differentially expressed miRNAs of the let-7 cluster and these miRNAs was analyzed. Five candidate genes (FOXP1, TBX5, HAND1, AKT2 and PPARGC1A), known to be involved in cardiac development were profiled. These five genes were located in the center of the network, whereas the remaining 37 genes, which were associated with the 5 candidate genes, were located on the edge of the network (Fig. 5).

Figure 5.

Network of target genes involved in heart development and let-7a/7d/7e/7f miRNAs.

Table VII.

Gene ontology analysis of targets of mmu-let-7a/7d/7e/7f.

Table VII.

Gene ontology analysis of targets of mmu-let-7a/7d/7e/7f.

Biological process category, nTargets of let-7aTargets of let-7dTargets of let-7eTargets of let-7f
Cell cycle and proliferation49514952
Stress response48474748
Transport9710710196
Developmental processes112111113115
RNA metabolism10197101104
DNA metabolism18151820
Other metabolic processes9897104100
Cell organization and biogenesis77777681
Cell-cell signaling14161513
Signal transduction102100101101
Cell adhesion21192120
Protein metabolism128122132127
Death35353534

Discussion

In the present study, we have characterized the miRNA expression profile in the developing mouse heart from E12.5 to E18.5 using next-generation sequencing. Currently, the most well-studied miRNAs are generally those that are expressed at the highest levels in tissues (22). The 10 top expressed miRNAs identified in the developing heart in the M1, M2, M3 and M4 groups are: mmu-miR-23b, mmu-miR-24, mmu-miR-23a, mmu-miR-375, mmu-miR-29a, mmu-miR-93, mmu-miR-21, mmu-miR-25, mmu-let-7b and mmu-miR-27b. This dataset has some overlap with previously published data on miRNA expression in the adult mouse heart (23–25); specifically, there are 3 miRNAs (mmu-miR-27b, mmu-miR-23a and mmu-miR-24) which appear to be highly abundant in both embryonic and adult hearts (Table VIII). These miRNAs have previously been investigated to assess their function in the heart, including the creation of cardiac-specific miRNA transgenic mice. For example, transgenic mice with cardiomyocyte-specific over-expression of miR-27b are able to induce cardiac hypertrophy and dysfunction (26), miR-23a transgenic mice also exhibit exaggerated cardiac hypertrophy (27), and transgenic mice with cardiac overexpression of miR-24 results in embryonic lethality (28). Given the insightful phenotypes observed in these mice, other miRNAs abundant in the developing heart should be investigated to gain a better understanding of the regulatory mechanisms of cardiac development.

Table VIII.

Top expressed miRNAs from the reported literature in adult mouse heart.

Table VIII.

Top expressed miRNAs from the reported literature in adult mouse heart.

Landgraf et al (23)
Takada et al (25)
Rao et al (24)
miRNA%miRNA%miRNA
mmu-miR-130.16 mmu-mir-126-3p/-5p20.84mmu-miR-1
mmu-miR-2088.73mmu-mir-117.37mmu-miR-29a
mmu-miR-1267.14mmu-mir-189/2413.40mmu-let-7c
mmu-miR-1433.17 mmu-mir-30e/30e*10.17mmu-let-7d
mmu-miR-26a3.17mmu-mir-1916.70mmu-miR-378
mmu-let-7d3.17mmu-mir-1435.21mmu-let-7f
mmu-miR-1443.17mmu-mir-124a4.22mmu-miR-26a
mmu-miR-4513.17mmu-mir-1442.48mmu-miR-143
mmu-miR-133a3.17mmu-mir-1451.49mmu-miR-24
mmu-miR-162.38mmu-let-7a1.49mmu-miR-30c
mmu-miR-222.38mmu-mir-29a1.24mmu-miR-133a
mmu-miR-27a2.38mmu-let-7a
mmu-miR-29b1.59mmu-miR-126
mmu-let-7c1.59mmu-miR-30d
mmu-miR-30a1.59mmu-miR-22
mmu-let-7a1.59mmu-miR-29c
mmu-let-7b1.59mmu-miR-125b
mmu-let-7f1.59mmu-miR-30a
mmu-miR-146a1.59mmu-miR-30e
mmu-miR-23a1.59mmu-miR-27b
  mmu-let-7b
mmu-miR-26b

Although some of the miRNAs identified as being highly abundant in the developing heart (i.e., mmu-miR-21, mmu-miR-25, mmu-miR-93 and mmu-miR-375) in this study, were not the top expressed miRNAs of the adult mouse heart (Table VIII), some of these miRNAs have previously been associated with heart function. For example, mmu-miR-21 is known as a differentiation-state-related miRNA (29), and as a cardiac muscle marker. Overexpression of miR-21 in a transgenic mouse heart resulted in suppression of the ischemia-induced upregulation of PTEN and FasL expression, a smaller infarct size, and ameliorated heart failure (30). Mmu-miR-25 and mmu-miR-93, both of which are in the miR-106b-25 cluster, also seem to have some significance for heart function. Transfection of miR-25 is sufficient to decrease the collagen gene expression in isolated cardiac fibroblasts in vitro (31), and miR-93 is downregulated during cardiac hypertrophy (32). It has also been postulated that miR-375 is a potential biomarker of acute ST-segment elevation myocardial infarction (33).

A third group of miRNAs to be considered are those that were highly abundant in the adult mouse heart (i.e., mmu-miR-1, mmu-miR-126 and mmu-miR-133a) (Table VIII), but were not in the top expressed miRNAs of the present study. Previous studies have shown that both miR-1 and miR-133 are important in the remodeling of the heart that occurs during cardiogenesis (34), and miR-126 has been shown to be sufficient to regulate vascular integrity and angiogenesis (35).

miRNAs may be expressed preferably during particular developmental time-points, or within certain tissues. Moreover, within a developmental framework, miRNAs may exhibit dynamic expression patterns (36). A major focus of our study was to define the repertoire of miRNAs expressed at different time-points of heart development. In terms of broad classes with expression that changed during development, two major expression profiles were identified: miRNAs expressed predominantly early in heart development and those expressed predominantly in the mature and developed heart. Our comparative clustering analyses have shown that there is 1 upregulated miRNA (mmu-miR-185) and 1 downregulated miRNA (mmu-miR-103) when we compared M1, M2, M3 and M4 (E12.5, early in heart development), respectively. This showed that the 2 highly conserved miRNA expression patterns at this point of heart development may be important, but no mechanistic studies investigating the relationship between these 2 miRNAs and heart development and function are currently available.

There are 3 upregulated miRNAs (mmu-miR-221, mmumiR-222, and mmu-miR-22) and 1 downregulated miRNA (mmu-miR-26b) differentially expressed when we compare M1 (E18.5, mature and developed heart) and M2, M3, M4, respectively. This showed that the 4 highly conserved miRNA expression patterns at this point of development may be important in heart and vascular development. miR-221 and miR-222 are known to be novel regulators for vascular smooth muscle cell proliferation (37), while miR-22-deficient mice show evidence of cardiac decompensation and left ventricular dilation (38). Overexpression of miR-26b in the heart was shown to inhibit upregulation of its targets and the development of hypertrophy (39).

For comparative analysis, we also profiled the differentially expressed microRNAs between the 4 different experimental time-points. Hierarchical cluster analysis showed a number of miRNAs that were differentially expressed during the investigated time frame of development, although no miRNAs were consistently downregulated or upregulated in the different groups. As such, we profiled the differentially expressed miRNAs between the later development (M1+M2) and early development (M3+M4) groups, and 3 downregulated and 13 upregulated miRNAs were identified. From this group of 16 differentially expressed miRNAs, let-7a/7d/7e/7f were all upregulated miRNAs that are known to be abundantly expressed in adult mouse heart tissue (24). Predicted targets of let-7a/7d/7e/7f are associated with developmental processes, cell organization and biogenesis, indicating profound biological changes occurring in the developing mouse heart. A network analysis of the predicted targets of let-7a/7d/7e/7f has shown that 5 target genes (FOXP1, TBX5, HAND1, AKT2 and PPARGC1A) are known to be involved in cardiac development (40). It is also known that these miRNAs, which are involved in mouse embryonic hearts, are able to regulate the expression of the 5 target genes by binding to a highly conserved target site in their 3′UTR.

In conclusion, our experiments identified a series of miRNAs abundantly expressed in the developing heart, as well as several differentially expressed miRNAs between late and early heart development. We believe that these miRNAs likely play an important role in heart development, thus additional studies may clarify the mechanism(s) of normal heart development, and provide a physiological basis for future investigations on congenital heart disease.

Acknowledgements

This study was supported by grants from the National Natural Science Foundation of China (Grant no. 81070500), the Key Medical Personnel Foundation of Jiangsu Province (Grant no. RC2011021), the Nanjing Medical Science and Technique Development Foundation, and the Science and Technology Development Foundation of Nanjing Medical University (Grant no. 2010NJMUZ15).

References

1. 

DP BartelMicroRNAs: genomics, biogenesis, mechanism, and functionCell116281297200410.1016/S0092-8674(04)00045-514744438

2. 

BP LewisCB BurgeDP BartelConserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targetsCell1201520200510.1016/j.cell.2004.12.03515652477

3. 

Y LiangD RidzonL WongC ChenCharacterization of microRNA expression profiles in normal human tissuesBMC Genomics8166200710.1186/1471-2164-8-16617565689

4. 

E WienholdsWP KloostermanE MiskaE Alvarez-SaavedraE BerezikovE de BruijnHR HorvitzS KauppinenRH PlasterkMicroRNA expression in zebrafish embryonic developmentScience309310311200510.1126/science.1114519

5. 

M Lagos-QuintanaR RauhutA YalcinJ MeyerW LendeckelT TuschlIdentification of tissue-specific microRNAs from mouseCurr Biol12735739200210.1016/S0960-9822(02)00809-612007417

6. 

L Hackler JrJ WanA SwaroopJ QianDJ ZackMicroRNA profile of the developing mouse retinaInvest Ophthalmol Vis Sci5118231831201010.1167/iovs.09-465719933188

7. 

KH LingPJ BrautiganCN HahnT DaishJR RaynerPS CheahJM RaisonS PiltzJR MannDM MattiskeDeep sequencing analysis of the developing mouse brain reveals a novel microRNABMC Genomics12176201110.1186/1471-2164-12-17621466694

8. 

B LiuGR CunhaLS BaskinDifferential expression of microRNAs in mouse embryonic bladderBiochem Biophys Res Commun385528533200910.1016/j.bbrc.2009.05.08819470377

9. 

T ThumD CatalucciJ BauersachsMicroRNAs: novel regulators in cardiac development and diseaseCardiovasc Res79562570200810.1093/cvr/cvn13718511432

10. 

D SayedC HongIY ChenJ LypowyM AbdellatifMicroRNAs play an essential role in the development of cardiac hypertrophyCirc Res100416424200710.1161/01.RES.0000257913.42552.2317234972

11. 

C SucharovMR BristowJD PortmiRNA expression in the failing human heart: functional correlatesJ Mol Cell Cardiol45185192200810.1016/j.yjmcc.2008.04.01418582896

12. 

RE vanLB SutherlandJE ThatcherJM DiMaioRH NaseemWS MarshallJA HillEN OlsonDysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosisProc Natl Acad Sci USA1051302713032200810.1073/pnas.080503810518723672

13. 

A CareD CatalucciF FelicettiD BonciA AddarioP GalloML BangP SegnaliniY GuND DaltonMicroRNA-133 controls cardiac hypertrophyNat Med13613618200710.1038/nm158217468766

14. 

RE vanLB SutherlandX QiJA RichardsonJ HillEN OlsonControl of stress-dependent cardiac growth and gene expression by a microRNAScience316575579200710.1126/science.113908917379774

15. 

Y ZhaoJF RansomA LiV VedanthamM von DrehleAN MuthT TsuchihashiMT McManusRJ SchwartzD SrivastavaDysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2Cell129303317200710.1016/j.cell.2007.03.03017397913

16. 

N LiuEN OlsonMicroRNA regulatory networks in cardiovascular developmentDev Cell18510525201010.1016/j.devcel.2010.03.01020412767

17. 

A StarkJ BrenneckeN BushatiRB RussellSM CohenAnimal MicroRNAs confer robustness to gene expression and have a significant impact on 3′UTR evolutionCell12311331146200516337999

18. 

A ChinchillaE LozanoH DaimiFJ EstebanC CristAE AranegaD FrancoMicroRNA profiling during mouse ventricular maturation: a role for miR-27 modulating Mef2c expressionCardiovasc Res8998108201110.1093/cvr/cvq26420736237

19. 

A WesselsD SedmeraDevelopmental anatomy of the heart: a tale of mice and manPhysiol Genomics15165176200310.1152/physiolgenomics.00033.200314612588

20. 

SM SavolainenJF FoleySA ElmoreHistology atlas of the developing mouse heart with emphasis on E11.5 to E18.5Toxicol Pathol37395414200910.1177/019262330933506019359541

21. 

ZB YuSP HanYF BaiC ZhuY PanXR GuomicroRNA expression profiling in fetal single ventricle malformation identified by deep sequencingInt J Mol Med295360201221935567

22. 

X WangX WangSystematic identification of microRNA functions by combining target prediction and expression profilingNucleic Acids Res3416461652200610.1093/nar/gkl06816549876

23. 

P LandgrafM RusuR SheridanA SewerN IovinoA AravinS PfefferA RiceAO KamphorstM LandthalerA mammalian microRNA expression atlas based on small RNA library sequencingCell12914011414200710.1016/j.cell.2007.04.04017604727

24. 

PK RaoY ToyamaHR ChiangS GuptaM BauerR MedvidF ReinhardtR LiaoM KriegerR JaenischLoss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failureCirc Res105585594200910.1161/CIRCRESAHA.109.20045119679836

25. 

S TakadaE BerezikovY YamashitaM Lagos-QuintanaWP KloostermanM EnomotoH HatanakaS FujiwaraH WatanabeM SodaMouse microRNA profiles determined with a new and sensitive cloning methodNucleic Acids Res34e115200610.1093/nar/gkl65316973894

26. 

J WangY SongY ZhangH XiaoQ SunN HouS GuoY WangK FanD ZhanCardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in miceCell Res22516527201210.1038/cr.2011.13221844895

27. 

K WangZQ LinB LongJH LiJ ZhouPF LiCardiac hypertrophy is positively regulated by MicroRNA miR-23aJ Biol Chem287589599201210.1074/jbc.M111.26694022084234

28. 

RE vanLB SutherlandN LiuAH WilliamsJ McAnallyRD GerardJA RichardsonEN OlsonA signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failureProc Natl Acad Sci USA1031825518260200610.1073/pnas.060879110317108080

29. 

MR SuhY LeeJY KimSK KimSH MoonJY LeeKY ChaHM ChungHS YoonSY MoonHuman embryonic stem cells express a unique set of microRNAsDev Biol270488498200410.1016/j.ydbio.2004.02.01915183728

30. 

D SayedM HeC HongS GaoS RaneZ YangM AbdellatifMicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligandJ Biol Chem2852028120290201010.1074/jbc.M110.10920720404348

31. 

V DivakaranJ AdrogueM IshiyamaML EntmanS HaudekN SivasubramanianDL MannAdaptive and maladptive effects of SMAD3 signaling in the adult heart after hemodynamic pressure overloadingCirc Heart Fail2633642200910.1161/CIRCHEARTFAILURE.108.82307019919989

32. 

PA Da Costa MartinsLJ De WindtMicroRNAs in control of cardiac hypertrophyCardiovasc Res93563572201222266752

33. 

Y D’AlessandraP DevannaF LimanaS StrainoCA DiPG BrambillaM RubinoMC CarenaL SpazzafumoM De SimoneCirculating microRNAs are new and sensitive biomarkers of myocardial infarctionEur Heart J3127652773201020534597

34. 

V DivakaranDL MannThe emerging role of microRNAs in cardiac remodeling and heart failureCirc Res10310721083200810.1161/CIRCRESAHA.108.18308718988904

35. 

S WangAB AuroraBA JohnsonX QiJ McAnallyJA HillJA RichardsonR Bassel-DubyEN OlsonThe endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesisDev Cell15261271200810.1016/j.devcel.2008.07.00218694565

36. 

F FaziC NerviMicroRNA: basic mechanisms and transcriptional regulatory networks for cell fate determinationCardiovasc Res79553561200810.1093/cvr/cvn15118539629

37. 

X LiuY ChengS ZhangY LinJ YangC ZhangA necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasiaCirc Res104476487200910.1161/CIRCRESAHA.108.18536319150885

38. 

P GurhaC Abreu-GoodgerT WangMO RamirezAL DrumondS van DongenY ChenN BartonicekAJ EnrightB LeeTargeted deletion of microRNA-22 promotes stress induced cardiac dilation and contractile dysfunctionCirculation12527512761201210.1161/CIRCULATIONAHA.111.04435422570371

39. 

M HanZ YangD SayedM HeS GaoL LinS YoonM AbdellatifGATA4 expression is primarily regulated via a miR-26b-dependent post-transcriptional mechanism during cardiac hypertrophyCardiovasc Res93645654201210.1093/cvr/cvs00122219180

40. 

VK KhodiyarDP HillD HoweTZ BerardiniS TweediePJ TalmudR BreckenridgeS BhattarcharyaP RileyP ScamblerRC LoveringThe representation of heart development in the gene ontologyDev Biol354917201110.1016/j.ydbio.2011.03.01121419760

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Cao L, Kong L, Yu Z, Han S, Bai Y, Zhu J, Hu X, Zhu C, Zhu S, Guo X, Guo X, et al: microRNA expression profiling of the developing mouse heart. Int J Mol Med 30: 1095-1104, 2012.
APA
Cao, L., Kong, L., Yu, Z., Han, S., Bai, Y., Zhu, J. ... Guo, X. (2012). microRNA expression profiling of the developing mouse heart. International Journal of Molecular Medicine, 30, 1095-1104. https://doi.org/10.3892/ijmm.2012.1092
MLA
Cao, L., Kong, L., Yu, Z., Han, S., Bai, Y., Zhu, J., Hu, X., Zhu, C., Zhu, S., Guo, X."microRNA expression profiling of the developing mouse heart". International Journal of Molecular Medicine 30.5 (2012): 1095-1104.
Chicago
Cao, L., Kong, L., Yu, Z., Han, S., Bai, Y., Zhu, J., Hu, X., Zhu, C., Zhu, S., Guo, X."microRNA expression profiling of the developing mouse heart". International Journal of Molecular Medicine 30, no. 5 (2012): 1095-1104. https://doi.org/10.3892/ijmm.2012.1092
Copy and paste a formatted citation
x
Spandidos Publications style
Cao L, Kong L, Yu Z, Han S, Bai Y, Zhu J, Hu X, Zhu C, Zhu S, Guo X, Guo X, et al: microRNA expression profiling of the developing mouse heart. Int J Mol Med 30: 1095-1104, 2012.
APA
Cao, L., Kong, L., Yu, Z., Han, S., Bai, Y., Zhu, J. ... Guo, X. (2012). microRNA expression profiling of the developing mouse heart. International Journal of Molecular Medicine, 30, 1095-1104. https://doi.org/10.3892/ijmm.2012.1092
MLA
Cao, L., Kong, L., Yu, Z., Han, S., Bai, Y., Zhu, J., Hu, X., Zhu, C., Zhu, S., Guo, X."microRNA expression profiling of the developing mouse heart". International Journal of Molecular Medicine 30.5 (2012): 1095-1104.
Chicago
Cao, L., Kong, L., Yu, Z., Han, S., Bai, Y., Zhu, J., Hu, X., Zhu, C., Zhu, S., Guo, X."microRNA expression profiling of the developing mouse heart". International Journal of Molecular Medicine 30, no. 5 (2012): 1095-1104. https://doi.org/10.3892/ijmm.2012.1092
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team